1. Home
  2. EMF vs MOLN Comparison

EMF vs MOLN Comparison

Compare EMF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$16.66

Market Cap

245.9M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.23

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EMF
MOLN
Founded
1987
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
245.9M
164.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EMF
MOLN
Price
$16.66
$4.23
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
29.3K
4.2K
Earning Date
01-01-0001
02-11-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.58
$3.36
52 Week High
$12.67
$5.91

Technical Indicators

Market Signals
Indicator
EMF
MOLN
Relative Strength Index (RSI) 42.68 49.23
Support Level $16.20 $4.20
Resistance Level $16.62 $4.60
Average True Range (ATR) 0.26 0.18
MACD -0.06 -0.01
Stochastic Oscillator 23.42 45.59

Price Performance

Historical Comparison
EMF
MOLN

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: